Ionis Pharmaceuticals (NASDAQ:IONS) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.07) by 60.75 percent. This is a 149.41 percent decrease over earnings of $0.85 per share from the same period last year. The company reported quarterly sales of $268.000 million which beat the analyst consensus estimate of $190.670 million by 40.56 percent. This is a 40.71 percent decrease over sales of $452.000 million the same period last year.